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Antinociceptive activity of a synthetic oxopyrrolidine-based compound, ASH21374, and 
determination of its possible mechanisms 
 
Abstract 
This study was carried out to determine the antinociceptive activity of a novel synthetic 
oxopyrrolidine-based compound, (2R,3R,4S)-ethyl 4-hydroxy-1,2-dimethyl-5-
oxopyrrolidine-3-carboxylate (ASH21374), and to elucidate the involvement of the opioid, 
vanilloid, glutamate, and nitric oxide – cyclic guanosine monophosphate (NO/cGMP) 
systems in modulating the observed antinociception. ASH21374, in the doses of 2, 10, and 
100 mg/kg body mass, was administered orally to mice 60 mins prior to exposure to various 
antinociceptive assays. From the results obtained, ASH21374 exhibited significant (P< 0.05) 
antinociceptive activity in the abdominal constriction, hot-plate, and formalin tests that was 
comparable with 100 mg/kg acetylsalicylic acid or 5 mg/kg morphine, respectively. 
ASH21374 also attenuated capsaicin- and glutamate-induced paw licking. Pre-treatment with 
5 mg/kg naloxone significantly (P< 0.05) inhibited the activity in all assays, while 
pretreatment with 10 mg/k-funaltraxamine, 1 mg/kg naltrindole, or 1 mg/kg nor-
binaltorphimine significantly (P< 0.05) reversed the activity in the abdominal constriction 
test. L-Arginine,NG-nitro-L-arginine methyl esters (L-NAME), methylene blue, and their 
combinations, failed to inhibit the ASH21374 antinociceptive activity. In conclusion, 
ASH21374 demonstrated antinociceptive activities on the peripheral and central nervous 
systems, mediated through the activation of opioid receptors, inhibition of the glutamatergic 
system, and attenuation of vanilloid-mediated nociceptive transmission. Further studies have 
been planned to determine the pharmacological potential of ASH21374. 
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